Tutorials

Good communication and sensitive delivery of information to patients and families is critical at all stages of a myeloma diagnosis and treatment. These tutorials demonstrate a number of different clinical scenarios and convey the patient experience in the HCP setting. The objective is to demonstrate best practice to help you improve the patient experience during…

Details

Related conditions

Treatment recommendations for patients with Waldenström’s Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM. Dimopoulos M et al. Blood. 2014 Jul 15. pii: blood-2014-03-565135. [Epub ahead of print]. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Weinhold N et al. Leukemia. 2014 Jul 3. doi: 10.1038/leu.2014.208. [Epub ahead of…

General

European Perspective on Multiple Myeloma Treatment Strategies in 2014. Ludwig H et al. Oncologist. 2014 Jul 25. pii: theoncologist.2014-0042. [Epub ahead of print]. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. Joks M et al. Eur J Haematol. 2014 Jul 10. doi: 10.1111/ejh.12412.…

Biology and genetics

Proteasome function is required for platelet production. Shi DS et al. J Clin Invest. 2014 Jul 25. pii: 75247. doi: 10.1172/JCI75247. [Epub ahead of print]. Overexpression of CYR61/CCN1 in the multiple myeloma microenvironment is associated with superior survival and prevention of bone disease. Johnson SK et al. Blood. 2014 Jul 24. pii: blood-2014-02-555813. [Epub ahead…

Complications of myeloma and its treatments

A Rare Concurrence: Nonischemic Cardiomyopathy and Multiple Myeloma Without Amyloidosis. Gupta T et al. Am J Med. 2014 Jul 21. pii: S0002-9343(14)00592-0. doi: 10.1016/j.amjmed.2014.07.012. [Epub ahead of print]. Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients. Fillatre P et al. Am J Med. 2014 Jul 21. pii: S0002-9343(14)00590-7. doi: 10.1016/j.amjmed.2014.07.010. [Epub…

Current treatments

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials. Huang H et al. Leuk Res. 2014 Jun 30. pii: S0145-2126(14)00188-X. doi: 10.1016/j.leukres.2014.06.009. [Epub ahead of print]. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple…